Lilly picks a Foghorn target; Mineralys’ $120M PIPE; Sana’s $165M offering

Plus, news about Telix, QSAM Biosciences, Nicox, and Kowa:

Eli Lilly selects Foghorn candidate for development: Foghorn’s stock $FHTX jumped 16% on Thursday morning after it said the pharma giant selected its oral BRM selective inhibitor for clinical development. The companies plan to test FHD-909 in patients with BRG1 mutated non-small cell lung cancer as part of a deal inked in 2021 that can provide up to $1.3 billion in milestones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Boston Scientific continues M&A run with Cortex buy

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Boston Scientific continued its active

November 4, 2024

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights – Psychedelic Alpha

• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical

June 28, 2023

Subsidiaries of Vita 34 reach agreement with US licensor – Biotech Investments

Vita 34 AG / Key word(s): Agreement/Scheme of Arrangement Subsidiaries of Vita 34 reach agreement with US licensor 09-Aug-2024 / 17:04 CET/CEST Disclosure of an

August 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.